Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
100 results about "Blood substitute" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A blood substitute (also called artificial blood or blood surrogate) is a substance used to mimic and fulfill some functions of biological blood. It aims to provide an alternative to blood transfusion, which is transferring blood or blood-based products from one person into another. Thus far, there are no well-accepted oxygen-carrying blood substitutes, which is the typical objective of a red blood cell transfusion; however, there are widely available non-blood volume expanders for cases where only volume restoration is required. These are helping doctors and surgeons avoid the risks of disease transmission and immune suppression, address the chronic blood donor shortage, and address the concerns of Jehovah's Witnesses and others who have religious objections to receiving transfused blood.
Method and apparatus for treating acute myocardial infarction with hypothermic perfusion
InactiveUS20050004503A1Optimal myocardial salvageRapid coolingStentsBalloon catheterVenous bloodCatheter device
An apparatus and method are described for quickly inducing therapeutic hypothermia of the heart by perfusing the myocardium with hypothermic fluid in alternatingly antegrade and retrograde directions. The apparatus and method provide rapid cooling of the affected myocardium to achieve optimal myocardial salvage in a patient experiencing acute myocardial infarction. The therapeutic hypothermia system includes one or more coronary artery perfusion catheters, a coronary sinus perfusion catheter and a fluid source for delivering a hypothermically-cooled physiologically-acceptable fluid, such as saline solution, oxygenated venous blood, autologously-oxygenated arterial blood and / or an oxygenated blood substitute. The system may also include one or more guidewires, subselective catheters and / or interventional catheters introduced through a lumen in one or more of the perfusion catheters.
Owner:CARDEON
Physiologically acceptable aqueous solutions and methods for their use
Artificial plasma-like solutions and methods for their use are provided. The subject solutions include: electrolytes and an oncotic agent. The subject solutions find use in a variety of applications, particularly in those applications where at least a portion of a host's blood volume is replaced with a blood substitute.
Owner:SEGALL PAUL E +3
Spectroscopic method and apparatus for analyte measurement
An apparatus and method for spectroscopic measurement of an analyte in a sample is provided. The apparatus comprises a source of electromagnetic radiation (EMR) producing a light path, an aperture located within the light path and between the EMR source and a sample slot, and a photodector. The apparatus also has a primary calibration algorithm that is in operative association with the spectroscopic apparatus. Examples of analytes that may be measured using this apparatus include, but are not limited to Total-Hemoglobin, Met-Hemoglobin, Hemoglobin-based blood substitutes and any Met-Hemoglobin equivalent. The measurement of Met-Hemoglobin may be used to provide an accurate measurement of Total-Hemoglobin in whole blood, or Hemoglobin when used as an indicator of hemolysis. The measurement of Met-Hemoglobin may also be also used as a means of monitoring the degradation or reversal of degradation of Hemoglobin-based blood substitutes, or as a means of monitoring the oxidation or reversal of oxidation of Hemoglobin to Met-Hemoglobin.
Owner:NIRESULTS
Preserving a hemoglobin blood substitute with a transparent overwrap
InactiveUS7041800B1High purityExtended shelf lifePeptide/protein ingredientsMetal layered productsPolyolefinMedicine
Owner:OPK BIOTECH
Oxygen delivery agents and uses for the same
InactiveUS7105151B2Ultrasonic/sonic/infrasonic diagnosticsPowder deliveryFluorinated gasesOxygen delivery
Owner:CEREVAST THERAPEUTICS
Alpha-keratose as a blood plasma expander and use thereof
InactiveUS6746836B1Improve convenienceFlexibilityDead animal preservationUnknown materialsDiseasePlasma expander
A plasma expander and blood substitute comprising a therapeutic amount if a solution of alpha-keratose, a soluble fraction of keratin, as an oncotic agent with nutrient growth properties suitable as a transport vehicle for the natural or synthetically formed elements of blood. The solution of alpha-keratose is non-antigenic, does not require blood typing, is free of disease producing viruses and may be stored indefinitely at ambient temperatures in the lyophilized state.
Owner:WIDRA ABE
Device and method for eliminating biologically harmful substances from bodily fluids
InactiveCN102725008ALower risk of deathGentle treatmentMembranesSemi-permeable membranesChemical synthesisMetabolite
Owner:HEMOTEQ AG +2
Oxygen delivery agents and uses for the same
InactiveUS20070059248A1Ultrasonic/sonic/infrasonic diagnosticsRespiratorsFluorinated gasesOxygen delivery
Owner:CEREVAST THERAPEUTICS
Method for monitoring degradation of Hb-based blood substitutes
InactiveUS6949384B2Analysis by material excitationAnalysis by subjecting material to chemical reactionPlasma samplesSerum samples
The present invention provides a method for monitoring degradation of Hb-based blood substitutes, in a sample. This method involves determining a concentration of met-Hb within the sample, by applying a calibration algorithm for met-Hb to an absorbance obtained from the sample at one or more than one wavelengths, and using the concentration of met-Hb, as a measurement of degradation of the Hb-based blood substitutes. Using this assay, a concentration of met-Hb that is equal to or greater than 3% may be used as an indicator of degradation of Hb. Alternatively, by obtaining samples over a period of time, the concentration of met-Hb and the concentration of Hb-based blood substitute may be determined in each of these samples, and an increase in the concentration of met-Hb over the period of time is an indicator of degradation of Hb. The sample may be a whole blood sample, a serum sample, or a plasma sample obtained from a patient transfused with one or more than one Hb-based blood substitutes, a stock Hb-based blood substitute sample, or a body part of a patient.
Owner:COVIDIEN LP
Ambient stored blood plasma expanders
ActiveUS20060051732A1Increased plasma volumeIncrease volumeBiocideOrganic active ingredientsBlood plasmaBlood substitute
A liquid plasma expander or resuscitation fluid composition for use in a subject in need thereof, comprising, consisting of, or consisting essentially of: (a) a keratin derivative (preferably alpha keratose, gamma keratose, or combinations thereof, and with basic alpha keratose preferred over acidic alpha keratose); and (b) an electrolyte solution, with the keratin derivative solubilized in the electrolyte solution to form a homogeneous liquid composition. Blood substitutes formed therefrom and methods of making and using the same are also described.
Owner:WAKE FOREST UNIV HEALTH SCI INC
Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
InactiveUS6894150B1Improve oxygen carrying capacityPeptide/protein ingredientsHaemoglobins/myoglobinsMammalBlood substitute
A non-pyrogenic, endotoxin-free, stroma-free, blood substitute capable of being used in humans or other mammals to provide oxygen to tissue and to deliver carbon dioxide to the lung and a process for its preparation are described.
Owner:IKOR +1
Preserving a hemoglobin blood substitute with a transparent overwrap
InactiveUS20060160724A1High purityExtended shelf lifeWrappersPeptide/protein ingredientsMedicineBlood substitute
The invention relates to a method for preserving the stability of a hemoglobin blood substitute comprising maintaining the hemoglobin blood substitute in an atmosphere substantially free of oxygen. The method for preserving the deoxygenated hemoglobin blood substitute comprises maintaining the deoxygenated blood substitute in an oxygen barrier film overwrap package, wherein at least one face of the overwrap package comprises a transparent laminate material and wherein at least one other face of the overwrap package comprises a foil laminate material. The preserved deoxygenated hemoglobin blood substitute comprises a deoxygenated hemoglobin blood substitute and an oxygen barrier film overwrap package wherein at least one face of the overwrap package comprises a transparent laminate material and wherein at least one other face of the overwrap package comprises a foil laminate material.
Owner:OPK BIOTECH
Ambient stored blood plasma expanders containing keratose
Owner:WAKE FOREST UNIV HEALTH SCI INC
Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
ActiveUS8808748B2Low oxygenation of tissueLow oxygenationPowder deliveryPeptide/protein ingredientsEthylene oxideHemeprotein
Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and / or polymersomes comprising of poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(γ-methyl ε-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties.
Owner:POSEIDA THERAPEUTICS INC
Process for abstracting high-purity hemoglobin from pig blood
InactiveCN101289493AGuaranteed pHReduce the chance of denaturation inactivationPeptide preparation methodsHigh concentrationAntioxidant
The invention relates to a method for extracting high-purity hemoglobin from pig blood, and on the condition of 2 to 6 DEG C, the following operations are carried out sequentially: first, anticoagulant pig blood is used for preparing packed red blood cells; hypotonic solution is used for dissolving packed red blood cells, in which inert gas is pumped, antioxidant is added, the pH value of the solution is adjusted and protective agent and antibacterial drugs are added, and after high-speed centrifugation, crude hemoglobin solution is obtained; toluene is added into the crude hemoglobin solution which is extracted in low temperature and the hemoglobin solution in the lower layer is extracted for dialysis; after being frozen and dried the hemoglobin solution after dialysis is then dissolved into high-concentration and small-volume liquid which is then purified by a sephadex chromatography column as a sample and high-concentration hemoglobin with even molecular weight is obtained to be frozen and dried in vacuum after being filtered for removing pyrogen so as to prepare high-concentration hemoglobin dry powder with no matrix or pyrogen. The hemoglobin obtained through the method of the invention has no matrix or pyrogen, which can be further modified to produce blood substitute safely and effectively and the operation is simple; the cost is low.
Owner:INST OF FIELD OPERATION SURGERY NO 3 MILITARY MEDICL UNIV PLA
Methods and compositions to reduce scattering of light during therapeutic and diagnostic imaging procedures
InactiveUS20050113678A1Reduce signal attenuationImprove image qualityDiagnostics using tomographySensorsBlood substituteIn vivo
Disclosed are improved methods and compositions for use in light-based in vivo imaging and treatment. The techniques described involve the use of low-scattering, oxygen-carrying blood substitutes in imaging and treatment methods, including OCT imaging. The invention has particular advantages in imaging within the cardiovascular system and highly vascularized or oxygen-dependent tissues.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Ferritin fusion proteins for use in vaccines and other applications
An isolated ferritin fusion protein is provided in which ferritin is fused with a protein or peptide capable of being fused to ferritin without interfering with the polymeric self-assembly of the resulting fusion protein, and the protein may be of the endocapsid form when fused at the C terminus or an exocapsid form when fused at the N terminus. These fusion proteins may self-assemble into a variety of useful higher polymeric forms, e.g., capsid or other polymeric aggregate, and they are advantageous in that they are useful in a variety of applications, including human and veterinary vaccines and therapeutics, blood substitutes, image contrast agents, metal chelating agents, gelling agents, protein purification platforms, and therapeutic receptor-binding proteins.
Owner:NEW CENTURY PHARMA INC
Methods of treating acute blood loss
InactiveUS7759306B2Blood lossRestore blood flowPeptide/protein ingredientsAntinoxious agentsCross-linkDouble-time
Owner:TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER
Hemoglobin conjugate and the preparation method and its use
InactiveUS20060247423A1Maintain osmotic pressureFunction is performedPeptide/protein ingredientsHaemoglobins/myoglobinsAnion-exchange chromatographyAlbumin
The present invention relates to conjugates of hemoglobin and human serum albumin and the preparation process thereof. The conjugates have molecular weight in the range of 100-300 kD, comprising 1-3 intermolecularly or intramolecularly cross-linked hemoglobin molecules and 1-3 human serum albumin molecules. The conjugates are obtained by the following steps: preparing stroma-free hemoglobin, then coupling hemoglobin to human serum albumin and purifying the products using anion exchange chromatography. The hemoglobin and human serum albumin conjugates have characteristics suitable for being used as blood substitutes.
Owner:INST OF PROCESS ENG CHINESE ACAD OF SCI
Water-soluble perfluorooctyl bromide-liposome nanosphere and preparation method thereof
InactiveCN103751106ASmall side effectsImprove stabilityHalogenated hydrocarbon active ingredientsEchographic/ultrasound-imaging preparationsIn vivoBiocompatibility
The invention relates to a water-soluble perfluorooctyl bromide-liposome nanosphere with a mean grain size of 30-800nm, the water-soluble perfluorooctyl bromide-liposome nanosphere structure is formed as follows: inner layer perfluorooctyl bromide (PFOB) is coated with outer layer lecithin bilayer to form a liposome nanosphere, the perfluorooctyl bromide-liposome nanosphere is negative in surface charge and is good in water-soluble property, an outer coating layer of the water-soluble perfluorooctyl bromide-liposome nanosphere is the well-biocompatible lecithin bilayer which can degrade in vivo, may not produce toxic and side effects on human body, the perfluorooctyl bromide-liposome nanosphere can be used as ultrasound diagnostic reagents and blood substitutes, and the particle size is easy to control and regulate, so that the application field is expanded. The preparation process of the perfluorooctyl bromide-liposome nanosphere is very simple in operation and low in requirement on equipment, and can be used for continuous production.
Owner:SHANGHAI NAT ENG RES CENT FORNANOTECH
Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
ActiveUS20110256225A1Low oxygenation of tissueLow oxygenationPowder deliveryBiocideEthylene oxideBlood substitute
Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and / or polymersomes comprising of poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(γ-methyl ε-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties.
Owner:POSEIDA THERAPEUTICS INC
Blood substitutes
The functional characteristics of heme proteins can be modified to produce hemoglobins that can be used as blood substitutes in different therapeutic applications. Stable polymers of tetrameric hemoglobin, and of myoglobin molecules, are provided for use in the blood substitutes.
Owner:TEMPLE UNIVERSITY +1
Carbide-derived-carbon-based oxygen carriers
InactiveUS20110151007A1Low cost mass productionIncrease productionPowder deliveryPeptide/protein ingredientsCombat casualtyCarbide
An oxygen delivery system is disclosed. The basis of the oxygen deliver system is a carbide-derived carbon (CDC). The CDC can be tuned to carry O2 directly (CDC OC), or hemoglobin can be adsorbed to provide a hemoglobin-based oxygen carrier (CDC HBOC). The delivery system allows the use of a variety of hemoglobins which differ in their oxygen dissociation profiles, including variant and mutant hemoglobins from other species. The delivery system is biocompatible and stable, and is able to irreversibly bind and hold large amounts of functional hemoglobin variants. The CDC HBOC and CDC OC provide a safe and effective blood substitute for combat casualty care, as well as being useful for oxygen delivery in other contexts.
Owner:BAE SYST INFORMATION & ELECTRONICS SYST INTERGRATION INC
Stable oxidation resistant powdered hemoglobin, methods of preparing same, and uses thereof
The present invention provides oxygenated hemoglobins in powdered form and methods of preparing a powdered form of a protein, such as hemoglobin, which comprise (a) mixing a solution of the protein with inulin, and optimally with a reducing sugar such as glucose or tagatose, and (b) drying the mixture. Also provided are blood substitutes formed from reconstituted powdered hemoglobins, and methods of treatment using the blood substitutes.
Owner:ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV
Deoxygenation method and preparation process for natural hemoglobin blood substitute
ActiveCN107137699APromote research and developmentGuaranteed activityPeptide/protein ingredientsPharmaceutical non-active ingredientsMethemoglobinCurative effect
The invention discloses a deoxygenation method for a natural hemoglobin blood substitute. The deoxygenation method comprises the following steps: adding a small molecule antioxidant and a sugar protective agent into an isotonic system containing natural hemoglobin; adjusting a pH value to 5.0 to 8.0; and alternatively vacuumizing and introducing high-purity inert gas for multiple deoxidization. The invention further discloses a preparation process for the natural hemoglobin blood substitute by adopting a deoxygenation technology. According to the deoxygenation method disclosed by the invention, thorough deoxygenation is realized by alternatively vacuumizing and introducing the gas for the multiple times; before deoxygenation, a proper amount of small molecule antioxygen is added for avoiding the phenomenon that the content of MetHb is increased caused by oxygen introduction before and after deoxygenation; compared with a method of deoxdation by only introducing the gas in the subsequent step in the prior art, the method disclosed by the invention has the advantages that deoxygenation is more thorough and quicker; the content of the hemoglobin is less than or equal to 1 percent, or even is as low as 0 percent; and in addition, a proper amount of sugar protectant is added before deoxygenation for sufficiently protecting a natural hemoglobin structure from being damaged in the deoxygenation process, so that activity and curative effect of a final product are ensured.
Owner:BLOOD TRASFUSION INST CHINESE ACAD OF MEDICAL SCI
Heme proteins hemAT-Hs and hemAT-Bs and their use in medicine and microsensors
The present invention provides an isolated archael and bacterial heme binding protein which reversibly binds oxygen with a low affinity. The heme binding protein may be utilized as a blood substitute. The invention also provides a method for controlled storage of oxygen by contacting a bacterial heme binding protein with oxygen allowing the protein to bind and store oxygen. The also provides methods to sense gaseous ligands using the heme binding protein. In other embodiments, the invention provides chimeric proteins having a heme-binding domain of an isolated heme binding archael bacterial protein and a heterologous signaling domain.
Owner:UNIV OF HAWAII
Oxygen-carrying blood substitute preparations
InactiveCN101264320ALow costPeptide/protein ingredientsPharmaceutical containersLiposome-encapsulated hemoglobinIn vivo
An oxygen-carrying blood substitute preparation stable upon storage is provided. The preparation comprises an oxygen-carrying substance capable of reversibly binding and releasing oxygen in vivo and an amount of a physiologically tolerable reducing agent effective for preventing at least partially irreversible oxidation of said oxygen-carrying substance. Preferably the oxygen-carrying substance is a hemoglobin-based substance in the form of a liposome encapsulating hemoglobin.
Owner:NIPRO CORP
Quality control material for reagentless measurement of analytes
InactiveUS20030138960A1Analysis by material excitationAnalysis by subjecting material to chemical reactionPlasma samplesAnalyte
The present invention provides a method for monitoring degradation of Hb-based blood substitutes, in a sample. This method comprises determining a concentration of met-Hb within the sample, by applying a calibration algorithm for met-Hb to an absorbance obtained from the sample at one or more than one wavelengths, and using the concentration of met-Hb, as a measurement of degradation of the Hb-based blood substitutes. Using this assay, a concentration of met-Hb that is equal to or greater than 3% may be used as an indicator of degradation of Hb. Alternatively, by obtaining samples over a period of time, the concentration of met-Hb and the concentration of Hb-based blood substitute may be determined in each of these samples, and an increase in the concentration of met-Hb over the period of time is an indicator of degradation of Hb. The sample may be a whole blood sample, a serum sample, or a plasma sample obtained from a patient transfused with one or more than one Hb-based blood substitutes, a stock Hb-based blood substitute sample, or a body part of a patient.
Owner:TYCO HEALTHCARE GRP LP
Methods and compositions to reduce scattering of light during therapeutic and diagnostic imaging procedures
InactiveUS7747315B2Rapid and high resolution imagingReduce signal attenuationDiagnostics using tomographySensorsVascularizesHematological test
Disclosed are improved methods and compositions for use in light-based in vivo imaging and treatment. The techniques described involve the use of low-scattering, oxygen-carrying blood substitutes in imaging and treatment methods, including OCT imaging. The invention has particular advantages in imaging within the cardiovascular system and highly vascularized or oxygen-dependent tissues.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
InactiveUS20160168228A1Improve subject survivalEffective treatmentPowder deliveryBacteriaElastin like polypeptidesNanoparticle
Described herein is the use of elastin-like polypeptides to generate hemoglobin-based oxygen carriers as a means of preventing and treating conditions caused by blood loss or anemia, for example, hemorrhagic shock. Elastin-like polypeptides are capable of creating therapeutically functional fusion proteins through genetic engineering with a therapeutic agent, for example, hemoglobin and biologic equivalent thereof. Specific forms of these fusion proteins have the ability to form into spherical nanoparticles possessing a therapeutically agent at their core. This provides a unique basis for employing elastin-like polypeptides as hemoglobin carriers in the manufacture of blood substitutes.
Owner:UNIV OF SOUTHERN CALIFORNIA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com